Clinical trials: Invasive Mold Infections
Invasive Mold Infections
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
The purpose of this study is to evaluate the efficacy and safety of fosmanogepix (administered IV or oral) for the treatment of adult patients with invasive mold infections.
- Trial name
- NCT06925321
- Testing
- Fosmanogepix IV infusion, Standard of care antifungal therapy, Fosmanogepix oral tablet
- Where
- 90 sites in United States, Australia and 13 more
- Volunteers
- 234 people
- Sponsor
- Basilea Pharmaceutica
Mycoses
Invasive Mould Infections in Indian ICUs - Descriptive Epidemiology, Management and Outcome
Invasive mould infections are emerging causes of morbidity and mortality in ICU patients. This is attributed to prolonged ICU stay of critically ill patients with many co-morbidities.
- Trial name
- NCT02683642
- Where
- 11 sites in India
- Volunteers
- 420 people
- Sponsor
- Fungal Infection Study Forum
Invasive Fungal Infection
Registry of Patients Treated With Systemic Mold-Active Triazoles
The purpose of this study is to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs), including invasive mold infection (IMI).
- Trial name
- NCT03066011
- Testing
- Isavuconazonium sulfate, Voriconazole, Posaconazole
- Where
- 56 sites in United States
- Volunteers
- 2,015 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Candidemia, Mycoses
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared to the standard antimicrobial regimen.
- Conditions
- Candidemia, Mycoses, Fungal Infection, Fungemia
- Trial name
- ReSPECT (NCT04368559)
- Testing
- Rezafungin for Injection, Posaconazole, Fluconazole
- Where
- 53 sites in United States, Belgium and 7 more
- Volunteers
- 602 people
- Sponsor
- Mundipharma Research Limited
Invasive Fungal Disease
Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi
This study is a post-approval commitment study, and is designed to further evaluate the safety and efficacy of isavuconazole in a relatively larger Chinese population who will receive isavuconazole treatment in a post-marketing…
- Trial name
- NCT05630976
- Testing
- Isavuconazole
- Where
- 14 sites in China
- Volunteers
- 70 people
- Sponsor
- Pfizer
Invasive Fungal Infections
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).
- Trial name
- AEGIS (NCT04240886)
- Testing
- fosmanogepix
- Where
- 15 sites in United States, Belgium and 2 more
- Volunteers
- 21 people
- Sponsor
- Basilea Pharmaceutica
Invasive Fungal Infections
Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections
The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment…
- Trial name
- NCT06433128
- Testing
- Fosmanogepix solution for infusion, Fosmanogepix 400 mg tablets
- Sponsor
- Basilea Pharmaceutica
Fungal Infection
CD5CAR-NK Cells for Refractory Invasive Mold Disease
CD5CAR-NK is a first-in-human, pilot, dose-escalation, and single-site study to evaluate the safety of CD5CAR-CBNK in patients with invasive mold diseases (IMD).
- Trial name
- CD5CAR-NK (NCT07454122)
- Testing
- CD5CAR-CBNK
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Aspergillosis
Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)
This study will test the effectiveness and the safety of giving two antifungal agents (voriconazole and anidulafungin) together to treat invasive aspergillosis in patients who are unable to tolerate polyene therapy.
- Trial name
- NCT00620074
- Testing
- voriconazole, anidulafungin
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Pfizer
Invasive Mould Infection
Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy
The purpose of this study is to determine if EL219 is safe and effective compared to liposomal amphotericin B (LAmB) or voricanozole for early treatment of invasive mould infections
- Trial name
- NCT07215273
- Testing
- EL219, Active Comparator- IV Antifungal (LAmB or voriconazole)
- Where
- 30 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Elion Therapeutics, Inc.
Aspergillos, Mucormye
Assessment of [18F]-Fluorocellobiose ([18F]FCB) Pharmacokinetics in Healthy Volunteers and Subjects With Invasive Mold Infections
Background: Fungal infections can cause serious disease in the lungs and other parts of the body. About 3.8 million people die with fungal infections each year.
- Conditions
- Aspergillos, Mucormye, Dimorphic, Other Molds
- Trial name
- NCT07704333
- Testing
- [18F]-Fluorocellobiose ([18F]FCB)
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Aspergillosis, Invasive Fungal Infections
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
The purpose of this study is to investigate the efficacy and safety of isavuconazole in the treatment of renally impaired participants with invasive fungal infections caused by Aspergillus and participants with invasive fungal…
- Trial name
- VITAL (NCT00634049)
- Testing
- isavuconazole
- Where
- 96 sites in United States, Argentina and 17 more
- Volunteers
- 149 people
- Sponsor
- Astellas Pharma Inc
Invasive Mold Infections, Breakthrough Invasive Mold Infections
Breakthrough Invasive Mold Infections Under Posaconazole Prophylaxis (BIMI)
Invasive mold infections (IMI) mainly affect patients with hematologic malignancies receiving intensive chemotherapy or after hematopoietic stem cell transplantation (HSCT).
- Conditions
- Invasive Mold Infections, Breakthrough Invasive Mold Infections, Hematologic Malignancy, Hematologic Diseases
- Trial name
- BIMI (NCT04720144)
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Leukemia, Myeloid, Acute, Acute Lymphoblastic Leukemia
Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment
The study aims to evaluate the occurrence, mortality, and risk factors for invasive mold infections (IMI) in children treated with chemotherapy for acute leukemia in Denmark.
- Trial name
- NCT05774990
- Where
- Denmark
- Volunteers
- 621 people
- Sponsor
- University of Southern Denmark
Fusariosis, Onychomycosis
Anti-mold Azole in the Prophylaxis for Invasive Fusariosis
Patients admitted for autologous or allogeneic hematopoietic cell transplantation, induction-remission chemotherapy for acute myeloid leukemia, myelodysplasia or acute lymphoid leukemia, or to receive immunosuppressive therapy…
- Trial name
- Fusarproph (NCT02714504)
- Testing
- Voriconazole or posaconazole
- Where
- Brazil
- Volunteers
- 239 people
- Sponsor
- Universidade Federal do Rio de Janeiro
Invasive Fungal Disease, Mold Invasive Fungal Infection: Aspergillus, Mucorales, Fusarium, Scedosporium
Immunomonitoring of Mold Invasive Infections
Mold invasive infections are associated with an important mortality despite optimization of the antifungal treatment. In a few case reports, immune checkpoints inhibitors, initially developed for neoplastic diseases, have shown a…
- Trial name
- IMMUNOFIL (NCT06285188)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis
Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
Background: The immune system is made up of special cells, tissues, and organs that fight infections. Problems with this system may lead to frequent, severe, or unusual fungal infections.
- Conditions
- Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis, CARD9, APECED
- Trial name
- NCT01386437
- Where
- United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Fungal Infection
A Trial Comparing Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing
This is a prospective, multicenter, randomized trial to study therapeutic drug monitoring (TDM) of voriconazole among patients with an invasive mould infection (IMI).
- Trial name
- VoriTDM (NCT01416025)
- Testing
- Prospective TDM Arm
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Johns Hopkins University
Invasive Aspergillosis
A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children
The purpose of this study is to evaluate the safety profile of voriconazole (an antifungal drug) when used in children who have invasive aspergillosis (IA) and other rare systemic fungal infections.
- Trial name
- NCT00836875
- Testing
- Voriconazole
- Where
- 25 sites in United States, Canada and 6 more
- Volunteers
- 31 people
- Sponsor
- Pfizer
Aspergillosis, Invasive Fungal Infection
Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
The purpose of this study is to compare the efficacy and safety of isavuconazole versus voriconazole in the treatment of patients with invasive aspergillosis.
- Trial name
- NCT00412893
- Testing
- Isavuconazole, Voriconazole
- Where
- 107 sites in United States, Argentina and 24 more
- Volunteers
- 527 people
- Sponsor
- Astellas Pharma Inc